Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
Background Recently, anti-programmed cell death protein 1 (PD-1)/programmed death-
ligand 1 (PD-L1) immunotherapy offers promising results for advanced biliary tract cancer …
ligand 1 (PD-L1) immunotherapy offers promising results for advanced biliary tract cancer …
[HTML][HTML] Unveiling the promise of PD1/PD-L1: a new dawn in immunotherapy for cholangiocarcinoma
F Chen, J Sheng, X Li, Z Gao, S Zhao, L Hu… - Biomedicine & …, 2024 - Elsevier
Cholangiocarcinoma (CCA), a rare yet notably aggressive cancer, has experienced a surge
in incidence in recent years. Presently, surgical resection remains the most effective curative …
in incidence in recent years. Presently, surgical resection remains the most effective curative …
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic …
Background A programmed cell death protein-1 (PD-1) inhibitor combined with lenvatinib
and Gemox chemotherapy as first-line therapy demonstrated high anti-tumor activity against …
and Gemox chemotherapy as first-line therapy demonstrated high anti-tumor activity against …
Evaluating the therapeutic potential of durvalumab in adults with locally advanced or metastatic biliary tract cancer: evidence to date
Advanced biliary tract cancers (BTCs) have historically been managed with chemotherapy
but, in recent years, this treatment paradigm has begun to shift with the introduction of …
but, in recent years, this treatment paradigm has begun to shift with the introduction of …
Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma
Background New treatment strategies are needed to improve outcomes for patients with
advanced cholangiocarcinoma (CCA) due to the limited efficacy of current first-line …
advanced cholangiocarcinoma (CCA) due to the limited efficacy of current first-line …
Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer
Objective To compare the treatment efficacy and safety of lenvatinib and programmed cell
death 1 (PD-1) inhibitor combined with oxaliplatin plus gemcitabine (Gemox) chemotherapy …
death 1 (PD-1) inhibitor combined with oxaliplatin plus gemcitabine (Gemox) chemotherapy …
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially …
S Wang, Y Wang, C Zhu, K Liu, J Chao… - … Journal of Surgery, 2024 - journals.lww.com
Background: The role of conversion surgery in patients with unresectable biliary tract cancer
who responded positively to PD-1/PD-L1 inhibitor-based therapy remains unclear. This …
who responded positively to PD-1/PD-L1 inhibitor-based therapy remains unclear. This …
Establishment of an ovarian cancer exhausted CD8+ T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq
T Hua, D Liu, X Zhang, S Li, J Wu, Q Zhao… - European Journal of …, 2024 - Springer
Ovarian cancer (OC) was the fifth leading cause of cancer death and the deadliest
gynecological cancer in women. This was largely attributed to its late diagnosis, high …
gynecological cancer in women. This was largely attributed to its late diagnosis, high …
Case report: translational treatment of unresectable intrahepatic cholangiocarcinoma: tislelizumab, Lenvatinib, and GEMOX in one case
H Zhang, H Yu - Frontiers in Oncology, 2024 - pmc.ncbi.nlm.nih.gov
Background Intrahepatic cholangiocellular carcinoma (ICC) is one of the most common
invasive malignancies. Currently, ICC is treated with radical surgical resection. However, the …
invasive malignancies. Currently, ICC is treated with radical surgical resection. However, the …
[HTML][HTML] Study on the mechanism of liver cancer immune escape mediated by MINDY1 through regulation of PD-L1 ubiquitination level
X Song, W Li, C Tian, X Ma, W Yang… - Biomolecules and …, 2025 - pmc.ncbi.nlm.nih.gov
The novel deubiquitinase enzyme, motif interacting with ubiquitin-containing novel DUB
family-1 (MINDY1), is highly expressed in liver cancer tissues and plays a crucial role in …
family-1 (MINDY1), is highly expressed in liver cancer tissues and plays a crucial role in …